Publications by authors named "L Rath"
Mountain forests provide not only wood as a raw material but also numerous ecosystem services, such as protection against natural hazards, recreation and carbon sequestration, and they are important hosts for biodiversity. To manage these forests efficiently and in a target-oriented manner, both forest management planning and efficient harvesting operations are required. However, in most cases these two aspects are handled independently from each other.
View Article and Find Full Text PDFBackground: The relationship between coronavirus disease 2019 (COVID-19) infection and multiple sclerosis (MS) relapse and disease progression remains unclear. Previous studies are limited by small sample sizes and most lack a propensity-matched control cohort.
Objective: To evaluate the effect of COVID-19 infection on MS disease course with a large propensity-matched cohort.
Article Synopsis
- - Cladribine (Mavenclad®) is an oral treatment for relapsing remitting multiple sclerosis (RRMS), but its effects on the immune system were previously unclear.
- - A Phase IV study with 41 RRMS patients showed that cladribine significantly reduced the count of certain monocytes and altered levels of cytokines, notably increasing CCL2 at week 1 post-treatment.
- - The study found that cladribine also affects the P2X7 receptor's activity, highlighting a new action mechanism that suggests further research into its potential use against other forms of MS and neurodegenerative diseases.
Background: The COVID-19 pandemic raised concern amongst clinicians that disease-modifying therapies (DMT), particularly anti-CD20 monoclonal antibodies (mAb) and fingolimod, could worsen COVID-19 in people with multiple sclerosis (pwMS). This study aimed to examine DMT prescribing trends pre- and post-pandemic onset.
Methods: A multi-centre longitudinal study with 8,771 participants from MSBase was conducted.
Background: In Australia, tixagevimab/cilgavimab 150 mg/150 mg was a government-funded pre-exposure prophylaxis for COVID-19 people with multiple sclerosis (pwMS) and other neuroimmunological conditions (pwNIc) treated with anti-CD20 antibodies or sphingosine-1-phosphate receptor modulators were eligible.
Objective: To analyse the roll-out, uptake and real-world efficacy of tixagevimab/cilgavimab in the prevention and severity of COVID-19. To assess compliance with uptake depending on the location of delivery.